Table 3.
Parameters | Case/Total | Survival rate, % | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
---|---|---|---|---|
MRR | ||||
Reference group | 100/168 | 22.57 | Reference | Reference |
Risk group | 53/80 | 12.93 | 1.40 (1.00–1.96) | 1.56 (1.02–2.37) |
Monocyte | ||||
Reference group | 119/200 | 20.66 | Reference | Reference |
Risk group | 34/49 | 13.83 | 1.53 (1.04–2.24) | 1.90 (1.16–3.11) |
MRR, monocyte-to-red blood cell count ratio; HR, hazard ratio; 95% CI, 95% confidence interval. Effect-size estimates were calculated under the COX proportional hazard regression models.
Adjusted HR was adjusted for age, gender, FVC (% predicted), DLCO (% predicted), Charlson Comorbidity Index, and drug therapy (steroids, N-acetylcysteine). P was calculated by Kaplan–Meier analysis. Cutoff values: 0.13 for MRR, 0.67 for monocyte.